Literature DB >> 6540237

Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: classification, morphology, clinical presentation and response to chemotherapy.

F R Appelbaum, G E Sale, R Storb, K Charrier, H J Deeg, T Graham, J C Wulff.   

Abstract

Forty cases of naturally occurring canine lymphoma were studied using a panel of murine monoclonal antibodies which identify defined subsets of normal canine lymphocytes. The distribution of phenotypes was similar to that which is seen in man in that the majority (78 per cent) of canine lymphomas were of B-cell origin but a definite minority were phenotypically of T-cell (10 per cent) or non-B, non-T-cell (12 per cent) origin. The expression of Ia-like antigens was restricted to B-cell neoplasms. Within each histologic subgroup of canine lymphomas there was considerable heterogeneity of cell surface marker expression. Immunophenotype appeared to correlate with clinical presentation. Finally, the reactivity of lymphoma cells with murine monoclonal antibody DLy-6, an antibody which appears to react with a differentiation antigen on canine B and T cells, strongly predicted the outcome of initial induction chemotherapy in that all ten evaluable dogs with DLy-6-tumors achieved complete responses to initial chemotherapy while only four of 11 dogs with DLy-6+ tumors responded completely.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6540237     DOI: 10.1002/hon.2900020205

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  9 in total

1.  Canine lymphoma-associated antigens defined by murine monoclonal antibodies.

Authors:  Z Steplewski; K A Jeglum; C Rosales; N Weintraub
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Molecular cytogenetic analysis of a novel high-grade canine T-lymphoblastic lymphoma demonstrating co-expression of CD3 and CD79a cell markers.

Authors:  R Thomas; K C Smith; R Gould; S M Gower; M M Binns; M Breen
Journal:  Chromosome Res       Date:  2001       Impact factor: 5.239

3.  Expression of the T200 family of glycoproteins in canine malignant lymphoma.

Authors:  U M Sarmiento; V E Valli
Journal:  Can J Vet Res       Date:  1987-01       Impact factor: 1.310

4.  The cytology, histology and prevalence of cell types in canine lymphoma classified according to the National Cancer Institute Working Formulation.

Authors:  R F Carter; V E Valli; J H Lumsden
Journal:  Can J Vet Res       Date:  1986-04       Impact factor: 1.310

5.  Canine cutaneous epitheliotropic lymphoma (mycosis fungoides) is a proliferative disorder of CD8+ T cells.

Authors:  P F Moore; T Olivry; D Naydan
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

6.  Rapid, effective and user-friendly immunophenotyping of canine lymphoma using a personal flow cytometer.

Authors:  Stratos Papakonstantinou; Inese Berzina; Amanda Lawlor; Emma J O'Neill; Peter J O'Brien
Journal:  Ir Vet J       Date:  2013-04-01       Impact factor: 2.146

7.  An Antibody Specific for the Dog Leukocyte Antigen DR (DLA-DR) and Its Novel Methotrexate Conjugate Inhibit the Growth of Canine B Cell Lymphoma.

Authors:  Marta Lisowska; Magdalena Milczarek; Jarosław Ciekot; Justyna Kutkowska; Wojciech Hildebrand; Andrzej Rapak; Arkadiusz Miazek
Journal:  Cancers (Basel)       Date:  2019-09-26       Impact factor: 6.639

Review 8.  Evolution of haematopoietic cell transplantation for canine blood disorders and a platform for solid organ transplantation.

Authors:  Scott S Graves; Rainer Storb
Journal:  Vet Med Sci       Date:  2021-08-14

9.  Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma.

Authors:  Kristen M Weishaar; Zachary M Wright; Mona P Rosenberg; Gerald S Post; Jennifer A McDaniel; Craig A Clifford; Brenda S Phillips; Philip J Bergman; Elissa K Randall; Anne C Avery; Douglas H Thamm; Abigail A Christman Hull; Cathy M Gust; Ann R Donoghue
Journal:  J Vet Intern Med       Date:  2021-12-24       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.